secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001384101-23-000161
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q3 2023 revenue up 19% to $90.1M; net loss widens on $34.9M impairment
-------------------------------------------------------------------------------

- Total revenue $90.1M, +19% YoY; testing revenue $82.0M, +27% YoY.
- Net loss $29.6M ($0.41 per share) vs $8.7M loss a year ago; includes $34.9M impairment from nCounter license.
- Total test volume 32,544, +23% YoY.
- Non-GAAP gross margin 69% vs 66% prior year; generated $14.2M cash from ops, cash $202.5M.
- Management cites strong demand for Decipher Prostate and Afirma tests driving growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410123000161/0001384101-23-000161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410123000161/vcyt-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001384101-23-000161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer